These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22952032)

  • 1. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
    Kim SP; Crispen PL; Thompson RH; Weight CJ; Boorjian SA; Costello BA; Lohse CM; Leibovich BC
    Cancer; 2012 Sep; 118(18):4412-20. PubMed ID: 22952032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.
    Wolff I; May M; Hoschke B; Zigeuner R; Cindolo L; Hutterer G; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Dalpiaz O; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin MD; Salzano L; Lotrecchiano G; Shariat SF; Hohenfellner M; Waidelich R; Stief C; Miller K; Pahernik S; Brookman-May S;
    Eur J Surg Oncol; 2016 May; 42(5):744-50. PubMed ID: 26899942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
    Doehn Ch; Richter A; Lehmacher W; Jocham D
    Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
    Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
    Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of renal cell carcinoma in children: a report from the Polish pediatric rare tumor study group.
    Stachowicz-Stencel T; Bien E; Balcerska A; Godzinski J; Synakiewicz A; Perek-Polnik M; Kurylak A; Pietras W; Kuzmicz M; Mizia-Malarz A; Rybczynska A; Nurzynska-Flak J
    Klin Padiatr; 2011 May; 223(3):138-41. PubMed ID: 21509711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current clinical trials in renal cell carcinoma.
    Sokoloff MH; Daneshmand S; Ryan CW
    Urol Oncol; 2005; 23(4):289-92. PubMed ID: 16018946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
    Sandhu SS; Symes A; A'Hern R; Sohaib SA; Eisen T; Gore M; Christmas TJ
    BJU Int; 2005 Mar; 95(4):522-5. PubMed ID: 15705072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.
    Repmann R; Goldschmidt AJ; Richter A
    Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
    Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant and adjuvant treatment of renal cell carcinoma.
    Thillai K; Allan S; Powles T; Rudman S; Chowdhury S
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
    Eggener SE; Yossepowitch O; Pettus JA; Snyder ME; Motzer RJ; Russo P
    J Clin Oncol; 2006 Jul; 24(19):3101-6. PubMed ID: 16809736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Blute ML; Cheville JC; Lohse CM; Frank I; Kwon ED; Weaver AL; Parker AS; Zincke H
    Cancer; 2003 Apr; 97(7):1663-71. PubMed ID: 12655523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.
    Kim SP; Weight CJ; Leibovich BC; Thompson RH; Costello BA; Cheville JC; Lohse CM; Boorjian SA
    Urology; 2011 Nov; 78(5):1101-6. PubMed ID: 21903243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
    Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
    Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy after nephrectomy for renal cell carcinoma.
    Ravaud A
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
    Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
    J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.